肝毒性とは - わかりやすく解説 Weblio辞書

すべての辞書から再検索する

ウィキペディア

索引トップランキングカテゴリー

肝毒性

出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2023/02/18 08:59 UTC 版)

肝毒性（Hepatotoxicity）とは、化学物質が肝障害を発症させる性質を意味する。また、薬剤性肝障害（Drug-induced liver injury）は、特に薬剤によって引き起こされる急性および慢性の肝疾患を指す用語である。

脚注

注釈

^ Council for International Organizations of Medical Sciences or Rousel Uclaf Causality Assessment Method scale

出典

^ 五野由佳理、小田口浩、早崎知幸、鈴木邦彦、及川哲郎、村主明彦、赤星透、花輪壽彦「漢方薬による薬物性肝障害の症例検討」『日本東洋醫學雜誌』第61巻第6号、日本東洋医学会、2010年9月、 828-833頁、 doi:10.3937/kampomed.61.828、 ISSN 02874857、 NAID 10026648875。
^ 萬谷直樹「漢方薬による肝障害:その診断，頻度，臨床像について」『日本東洋医学雑誌』第66巻第4号、日本東洋医学会、2015年、 342-351頁、 doi:10.3937/kampomed.66.342、 ISSN 0287-4857、 NAID 130005125822。
^ Friedman, Scott E.; Grendell, James H.; McQuaid, Kenneth R. (2003). Current diagnosis & treatment in gastroenterology. New York: Lang Medical Books/McGraw-Hill. pp. 664–679. ISBN 978-0-8385-1551-8
^ ^a ^b Dixit, Vaibhav A. (2019). “A simple model to solve a complex drug toxicity problem”. Toxicology Research 8 (2): 157–171. doi:10.1039/C8TX00261D. PMC 6417485. PMID 30997019.
^ “Stem Cell-Based Toxicity Screening: Recent Advances in Hepatocyte Generation”. Pharm Med 26 (2): 85–89. (2012). doi:10.1007/BF03256896.
^ McNally, Peter F. (2006). GI/Liver Secrets: with STUDENT CONSULT Access. Saint Louis: C.V. Mosby. ISBN 978-1-56053-618-5
^ “Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States”. Ann. Intern. Med. 137 (12): 947–54. (2002). doi:10.7326/0003-4819-137-12-200212170-00007. PMID 12484709.
^ Davies, D. (1985). Textbook of adverse drug reactions. Oxford [Oxfordshire]: Oxford University Press. pp. 18–45. ISBN 978-0-19-261479-7. OCLC 12558288
^ “Adverse drug reactions”. BMJ 316 (7140): 1295–8. (1998). doi:10.1136/bmj.316.7140.1295. PMC 1113033. PMID 9554902.
^ Zimmerman HJ (1978). “Drug-induced liver disease”. Drugs 16 (1): 25–45. doi:10.2165/00003495-197816010-00002. PMID 352664.
^ Dixit, Vaibhav A.; Bharatam, Prasad V. (18 July 2011). “Toxic Metabolite Formation from Troglitazone (TGZ): New Insights from a DFT Study”. Chemical Research in Toxicology 24 (7): 1113–1122. doi:10.1021/tx200110h. PMID 21657230.
^ “Ketoconazole Tablets”. 2021年9月21日閲覧。
^ Banankhah, Peymaan S.; Garnick, Kyle A.; Greenblatt, David J. (2016-02-01). “Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers”. Journal of Clinical Pharmacology 56 (10): 1196–202. doi:10.1002/jcph.711. ISSN 1552-4604. PMID 26829173.
^ ^a ^b Keeffe, Emmet B; Friedman, Lawrence M. (2004). Handbook of liver diseases. Edinburgh: Churchill Livingstone. pp. 104–123. ISBN 978-0-443-06633-7
^ Wallace JL (2004). “Acetaminophen hepatotoxicity: NO to the rescue”. Br. J. Pharmacol. 143 (1): 1–2. doi:10.1038/sj.bjp.0705781. PMC 1575258. PMID 15345657.
^ “Acetaminophen-induced hepatotoxicity”. Drug Metab. Dispos. 31 (12): 1499–506. (2003). doi:10.1124/dmd.31.12.1499. PMID 14625346.
^ “Hepatotoxicity of anti-inflammatory and analgesic drugs: ultrastructural aspects”. Acta Pharmacol. Sin. 27 (3): 259–72. (2006). doi:10.1111/j.1745-7254.2006.00278.x. PMID 16490160.
^ “Hepatomegaly following short-term high-dose steroid therapy”. J. Pediatr. Gastroenterol. Nutr. 5 (1): 41–6. (1986). doi:10.1097/00005176-198601000-00008. PMID 3944744.
^ Alpers DH, Sabesin SM (1982). Schiff L. ed. Diseases of the liver. Philadelphia: JB Lippincott. pp. 813–45
^ “Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor”. J. Pharmacol. Exp. Ther. 289 (2): 695–702. (1999). PMID 10215642.
^ Schläppi B (1984). “The lack of hepatotoxicity in the rat with the new and reversible MAO-A inhibitor moclobemide in contrast to iproniazid”. Arzneimittel-Forschung 35 (5): 800–803. PMID 4026902.
^ Cook G. C.; Sherlock S. (1965). “Jaundice and its relation to therapeutic agents”. The Lancet 285 (7378): 175–179. doi:10.1016/s0140-6736(65)90969-4. PMID 14238042.
^ Kothari U. C. (1960). “Toxic and Other Side Effects of Nardil Phenelzine Sulphate W-1544A”. American Journal of Psychiatry 116 (8): 746–747. doi:10.1176/ajp.116.8.746. PMID 14411298.
^ “Amoxicillin”. Davis (2017年). 2017年3月24日閲覧。
^ “Foodborne Pathogenic Microorganisms and Natural Toxins Handbook: Pyrrolizidine Alkaloids”. Bad Bug Book. United States Food and Drug Administration. 2009年7月11日閲覧。
^ Schoental, R.; Kelly, JS (April 1959). “Liver lesions in young rats suckled by mothers treated with the pyrrolizidine (Senecio) alkaloids, lasiocarpine and retrorsine.”. The Journal of Pathology and Bacteriology 77 (2): 485–495. doi:10.1002/path.1700770220. PMID 13642195.
^ “GreenTea”. 2021年9月21日閲覧。
^ “Liver Damage from Supplements is on the Rise”. 2021年9月21日閲覧。
^ Chalasani, Naga P.; Hayashi, Paul H.; Bonkovsky, Herbert L.; Navarro, Victor J.; Lee, William M.; Fontana, Robert J.; Practice Parameters Committee of the American College of Gastroenterology (2014). “ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury”. The American Journal of Gastroenterology 109 (7): 950–966. doi:10.1038/ajg.2014.131. PMID 24935270.
^ Kim, Young-Je (2013). “Garcinia Cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation”. World Journal of Gastroenterology 19 (29): 4689–701. doi:10.3748/wjg.v19.i29.4689. PMC 3732841. PMID 23922466.
^ Zhou, P.; Gross, S.; Liu, J.-H.; Yu, B.-Y.; Feng, L.-L.; Nolta, J.; Sharma, V.; Piwnica-Worms, D. et al. (2010). “Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF- B and MAPK signaling pathways”. The FASEB Journal 24 (12): 4722–32. doi:10.1096/fj.10-163311. PMC 2992378. PMID 20696856.
^ Pak, E; Esrason, KT; Wu, VH (2004). “Hepatotoxicity of herbal remedies: an emerging dilemma”. Progress in Transplantation 14 (2): 91–6. doi:10.7182/prtr.14.2.k7743w3j64855180. PMID 15264453.
^ McRae, CA; Agarwal, K; Mutimer, D; Bassendine, MF (2002). “Hepatitis associated with Chinese herbs”. European Journal of Gastroenterology & Hepatology 14 (5): 559–62. doi:10.1097/00042737-200205000-00015. PMID 11984156.
^ Furukawa, Maiko; Kasajima, Saeko; Nakamura, Yuri; Shouzushima, Meiko; Nagatani, Naho; Takinishi, Akira; Taguchi, Ayumi; Fujita, Mikiko et al. (2010). “Toxic Hepatitis Induced by Show-Wu-Pian, a Chinese Herbal Preparation”. Internal Medicine 49 (15): 1537–40. doi:10.2169/internalmedicine.49.3509. PMID 20686286.
^ Kumar, EP; Kumar, AnilD; Parasuraman, S; Rajan, VijayR; Emerson, SF (2013). “Hepatoprotective activity of Clearliv a polyherbal formulation in Wistar rats”. Archives of Medicine and Health Sciences 1 (2): 120–5. doi:10.4103/2321-4848.123023.
^ “Mechanisms of hepatotoxicity”. Toxicol. Sci. 65 (2): 166–76. (2002). doi:10.1093/toxsci/65.2.166. PMID 11812920.
^ “Dysregulation of apoptosis as a mechanism of liver disease: an overview”. Semin. Liver Dis. 18 (2): 105–14. (1998). doi:10.1055/s-2007-1007147. PMID 9606808.
^ Donald Blumenthal; Laurence Brunton; Keith Parker; Lazo, John S.; Iain Buxton (2006). Goodman and Gilman's Pharmacological Basis of Therapeutics Digital Edition. McGraw-Hill Professional. ISBN 978-0-07-146804-6
^ Michalets EL (1998). “Update: clinically significant cytochrome P-450 drug interactions”. Pharmacotherapy 18 (1): 84–112. doi:10.1002/j.1875-9114.1998.tb03830.x. PMID 9469685.
^ “The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects”. American Family Physician 76 (3): 391–6. (2007). PMID 17708140.
^ ^a ^b “Drug-related hepatotoxicity”. N. Engl. J. Med. 354 (20): 2191–3; author reply 2191–3. (2006). doi:10.1056/NEJMc060733. PMID 16710915.
^ Bénichou C (1990). “Criteria of drug-induced liver disorders. Report of an international consensus meeting”. J. Hepatol. 11 (2): 272–6. doi:10.1016/0168-8278(90)90124-A. PMID 2254635.
^ ^a ^b ^c “Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists”. World J. Gastroenterol. 13 (3): 329–40. (2007). doi:10.3748/wjg.v13.i3.329. PMC 4065885. PMID 17230599.
^ “Drug-induced liver disease in 2006”. Curr. Opin. Gastroenterol. 23 (3): 244–54. (2007). doi:10.1097/MOG.0b013e3280b17dfb. PMID 17414839.
^ Maria and Victorino (M & V) System of Causality Assessment in Drug Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases, (2012), PMID 31689019 2021年9月21日閲覧。
^ Reuben A (2004). “Hy's law”. Hepatology 39 (2): 574–8. doi:10.1002/hep.20081. PMID 14768020.
^ “Anticoagulants and transaminase elevation”. Circulation 113 (15): e698–702. (2006). doi:10.1161/CIRCULATIONAHA.105.603100. PMID 16618822.
^ “Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry”. Hepatology 44 (6): 1581–8. (2006). doi:10.1002/hep.21424. PMID 17133470.
^ “Outcome and prognostic markers in severe drug-induced liver disease”. Hepatology 42 (2): 481–9. (2005). doi:10.1002/hep.20800. PMID 16025496.
^ Shah RR (1999). “Drug-induced hepatotoxicity: pharmacokinetic perspectives and strategies for risk reduction”. Adverse Drug Reactions and Toxicological Reviews 18 (4): 181–233. PMID 10687025.
^ Drug-Induced Hepatotoxicity - eMedicine